These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network. Viscidi R, Ellerbeck E, Garrison L, Midthun K, Clements ML, Clayman B, Fernie B, Smith G. AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607 [Abstract] [Full Text] [Related]
6. Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes infected individuals grouped according to CD4+ cell levels. Warren RQ, Wolf H, Zajac RA, Boswell RN, Kanda P, Kennedy RC. J Clin Immunol; 1991 Jan; 11(1):13-21. PubMed ID: 1708780 [Abstract] [Full Text] [Related]
7. Fine specificity of the humoral immune response to HIV-1 GP160 in HIV-1 infected individuals from Tanzania. Nkya WM, Warren RQ, Wolf H, Hendrix CW, Tesha J, Redfield RR, Melcher GP, Burke DS, Kanda P, Kennedy RC. J Med Virol; 1992 May; 37(1):61-6. PubMed ID: 1619399 [Abstract] [Full Text] [Related]
8. Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees. Warren RQ, Wolf H, Shuler KR, Eichberg JW, Zajac RA, Boswell RN, Kanda P, Kennedy RC. J Virol; 1990 Feb; 64(2):486-92. PubMed ID: 2404138 [Abstract] [Full Text] [Related]
9. Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network. Gorse GJ, Frey SE, Newman FK, Belshe RB. J Clin Microbiol; 1992 Oct; 30(10):2606-12. PubMed ID: 1400960 [Abstract] [Full Text] [Related]
11. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Mosier DE, Gulizia RJ, MacIsaac PD, Corey L, Greenberg PD. Proc Natl Acad Sci U S A; 1993 Mar 15; 90(6):2443-7. PubMed ID: 8460155 [Abstract] [Full Text] [Related]
12. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein. Zaghouani H, Hall B, Shah H, Bona C. Adv Exp Med Biol; 1991 Mar 15; 303():53-62. PubMed ID: 1725238 [No Abstract] [Full Text] [Related]
17. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160. Benjouad A, Gluckman JC, Montagnier L, Bahraoui E. J Virol; 1993 Mar 15; 67(3):1693-7. PubMed ID: 7679751 [Abstract] [Full Text] [Related]
20. Immunization of chimpanzees with recombinant gp160, but not infection with human immunodeficiency virus type 1, induces envelope-specific Th1 memory cells. Mannhalter JW, Fischer MB, Wolf HM, Küpcü Z, Barrett N, Dorner F, Eder G, Eibl MM. J Infect Dis; 1995 Feb 15; 171(2):437-40. PubMed ID: 7844384 [Abstract] [Full Text] [Related] Page: [Next] [New Search]